Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.67 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.66 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.66 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.62 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | CHRND | Q07001 | 5/20 | 0.56 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.56 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.56 |
| ▸ | CHRNG | P07510 | 1/20 | 0.56 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17204342 | 1.00 | FAAH (0.67) | FAAHITGB3ITGA2BGRIA1CNR1 | |
| SCHEMBL16466484 | 1.00 | FAAH (0.67) | FAAHITGB3ITGA2BGRIA1CNR1 | |
| SCHEMBL3802383 | 1.00 | FAAH (0.67) | FAAHITGB3ITGA2BGRIA1CNR1 | |
| SCHEMBL15121449 | 1.00 | FAAH (0.67) | FAAHITGB3ITGA2BGRIA1CNR1 | |
| SCHEMBL4581442 | 1.00 | FAAH (0.67) | FAAHITGB3ITGA2BGRIA1CNR1 | |
| SCHEMBL8371124 | 1.00 | FAAH (0.67) | FAAHITGB3ITGA2BGRIA1CNR1 | |
| SCHEMBL29026 | 1.00 | FAAH (0.67) | FAAHITGB3ITGA2BGRIA1CNR1 | |
| SCHEMBL17204106 | 1.00 | FAAH (0.67) | FAAHITGB3ITGA2BGRIA1CNR1 | |
| SCHEMBL6651208 | 1.00 | FAAH (0.67) | FAAHITGB3ITGA2BGRIA1CNR1 | |
| SCHEMBL4582828 | 1.00 | FAAH (0.67) | FAAHITGB3ITGA2BGRIA1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087250-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2021-03-25 | — | — | US | claimed |
| EP-3006045-B3 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | CYPRUMED GMBH (AT) | 2021-03-17 | — | — | EP | claimed |
| EP-3773475-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | Cyprumed GmbH (AT) | 2021-02-17 | — | — | EP | claimed |
| WO-2019193204-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2019-10-10 | — | — | WO | claimed |
| EP-3204045-B1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2018-12-05 | — | — | EP | claimed |
| US-20180280481-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | CYPRUMED GMBH (AT) | 2018-10-04 | — | — | US | claimed |
| CN-108135962-A | For the pharmaceutical preparation of oral delivery peptide medicament | 塞浦路迈德有限责任公司 | 2018-06-08 | — | — | CN | claimed |
| US-20170304195-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2017-10-26 | — | — | US | claimed |
| EP-3204045-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | Cyprumed GmbH (AT) | 2017-08-16 | — | — | EP | claimed |
| WO-2017060500-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | CYPRUMED GMBH (AT) | 2017-04-13 | — | — | WO | claimed |
| EP-3006045-B1 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | CYPRUMED GMBH (AT) | 2017-04-12 | — | — | EP | claimed |
| WO-2016055550-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2016-04-14 | — | — | WO | claimed |
| EP-3006045-A1 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | Cyprumed GmbH (AT) | 2016-04-13 | — | — | EP | claimed |
| US-20140056953-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | NOVO NORDISK A/S (DK) | 2014-02-27 | — | — | US | claimed |
| EP-2696847-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | Novo Nordisk A/S (DK) | 2014-02-19 | — | — | EP | claimed |
| WO-2012140155-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | NOVO NORDISK A/S (DK) | 2012-10-18 | — | — | WO | claimed |
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | LE ROUX DANIELLE MARIE (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2026-01-29 | — | — | US | disclosed |
| EP-1888180-A2 | SELF-TANNING COMPOSITION HAVING A UV PROTECTIVE EFFECT | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006131247-A2 | SELF-TANNING COMPOSITION HAVING A UV PROTECTIVE EFFECT | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304195-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | SLC30A5, SLC30A6, SON | FAAH 4519/4885ITGB3 4040/4885ITGA2B 4451/4885 |
| US-20180280481-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | SLC30A5, SLC39A11, SLC30A6 | FAAH 4365/4885ITGB3 3498/4885ITGA2B 3831/4885 |
| US-20210087250-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | VIP, PTMS, VASP | FAAH 3710/4885ITGB3 1117/4885ITGA2B 1639/4885 |
| US-20140056953-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | SLC27A1, SLC27A2, FABP2 | FAAH 63/4885ITGB3 2947/4885ITGA2B 1339/4885 |
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | ADM2, TAS2R42, ACP1 | FAAH 3546/4885ITGB3 1256/4885ITGA2B 695/4885 |
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | VIP, GIPR, SLC10A2 | FAAH 1139/4885ITGB3 4548/4885ITGA2B 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.